Aims: Despite proven benefits of LDL-C lowering among those with atherosclerotic cardiovascular disease (ASCVD), statin adherence remains low. Very little real-world data exist on the effect of long-term statin adherence on cardiovascular outcomes.

Methods And Results: A total of 7339 patients ≥18 years first diagnosed with ASCVD with a statin prescription within 12 months of diagnosis who had 5 years of continuous Select Health insurance or died during Years 2-5, while a member was studied. The proportion of days covered (PDC) was calculated using pharmacy claims for statin use by year, and patients were stratified into pre-defined categories: fully adherent [PDC ≥ 80% for Years 1-5 or until death, n = 353 (4.8%)], short-term-adherent [PDC ≥ 80% for Years 1-3, n = 330 (4.5%)], early-adherent only [PDC ≥ 80% for Year 1, n = 890 (12.1%)], complex-adherent (PDC ≥ 80% in any of Years 2-5, but not Year 1, n = 1292 [17.6%]), and non-adherent [PDC < 80% for Years 1-5 or until death, n = 3942 (72.1%)]. Patients were followed for major adverse clinical events (MACE = death, myocardial infarction, and stroke). Patients averaged 56.4 ± 9.6 years and 76.5% were male. During Year 1, statin adherence was poor, with PDC < 20% in 4007 (54.6%) patients and PDC ≥80% in 1573 (21.4%) patients, which dropped to 16.9% by Year 5. Increased adherence was associated with significantly fewer MACE (11.6%, 17.9%, 21.9%, 21.1%, and 26.4% for those fully adherent, short-term adherent, early-adherent only, complex-adherent, and non-adherent, respectively, P-trend < 0.0001). After adjustment, fully adherent was associated with a significant decrease in MACE (hazard ratio = 0.51, 0.37-0.71).

Conclusion: Among ASCVD patients with at least 5 years of continuous pharmacy benefits, long-term adherence to statins was associated with decreased long-term MACE in a linear-fashion.

Download full-text PDF

Source
http://dx.doi.org/10.1093/ehjqcco/qcab024DOI Listing

Publication Analysis

Top Keywords

atherosclerotic cardiovascular
8
cardiovascular disease
8
ascvd statin
8
statin adherence
8
years 2-5
8
[pdc ≥ 80% years
8
years
6
high-statin adherence
4
adherence years
4
years follow-up
4

Similar Publications

Background: Atherosclerosis, a leading cause of cardiovascular disease, is characterized by intricate interactions among lipid metabolism, inflammation, and immune response. Investigating immune-related genetic factors and immune cell infiltration in atherosclerotic tissues may provide insights into potential therapeutic targets.

Methods: We analyzed transcriptomic data from atherosclerotic and normal tissues to identify differentially expressed genes (DEGs).

View Article and Find Full Text PDF

Statin therapy in primary and secondary cardiovascular disease prevention.

Curr Atheroscler Rep

December 2024

Hellenic Endocrine Network, 6, Ermou St, Athens, Greece.

Purpose Of Review: Atherosclerotic cardiovascular disease (ASCVD) is one of the most common causes of death globally and the leading one in the US. Elevated low-density lipoprotein (LDL) cholesterol is one of the main modifiable disease risk factors and statin therapies have been extensively studied in that regard. The present work presents the clinical trials derived evidence supporting the use of statins in primary and secondary cardiovascular disease prevention.

View Article and Find Full Text PDF

Background And Objective: Neutrophil extracellular traps (NETs) with inflammatory risk are important contributors to cardiovascular disease, but no definitive information is available in large artery atherosclerotic (LAA) stroke. This study aims to investigate the association between NETs with related inflammatory biomarkers and prognosis of LAA stroke in the Chinese population.

Methods: A prospective study involving 145 LAA stroke cases and 121 healthy controls was conducted.

View Article and Find Full Text PDF

Background: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality globally. Hypercholesterolemia accelerates atherosclerotic development and is an independent modifiable risk factor for ASCVD. Reducing cholesterol levels is effective in preventing ASCVD.

View Article and Find Full Text PDF

Mmu_circ_0001148 promotes endothlial-mesenchymal transition via regulating miR-218-5p/JMY axis and drives progression of atherosclerosis.

Int J Biol Macromol

December 2024

Department of Physiology, School of Basic Medicine, Bengbu Medical University, Bengbu 233000, Anhui, China; Key Laboratory of Basic and Clinical Cardiovascular Diseases, Bengbu Medical University, Bengbu 233000, Anhui, China. Electronic address:

Atherosclerosis (AS) is a common cardiovascular disease and responsible for the high mortality of cardiovascular emergencies. Circular RNAs (circRNAs) show a potential role in atherogenesis. We identified an aberrantly expressed circRNA (circ_0001148) in atherosclerotic tissues.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!